Breaking News

Janssen Acquires Bavarian Nordic’s MVA-BN Technology

Gains exclusive rights to use MVA-BN in a prime-boost vaccine regimen to target all HPV cancers

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bavarian Nordic has entered into a license and collaboration agreement with Janssen Pharmaceuticals under which, Janssen will acquire exclusive rights to Bavarian Nordic’s MVA-BN technology for use in a prime-boost vaccine regimen to target all cancers induced by human papillomavirus (HPV).   Bavarian Nordic will receive $9 million upfront, as well as potential development and commercial milestones, together totaling as much as $171 million. Janssen will fund all development costs, and B...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters